The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe" sickle cell disease

Blood

Volumn 124, Issue 6, 2014, Pages 861-866

  Nickel, Robert S ^a   Hendrickson, Jeanne E ^b   Haight, Ann E ^a  

^a EMORY UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD SAFETY; DISEASE SEVERITY; EQUIPOISE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; JUSTICE; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT HARM; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; CHILD; CLINICAL TRIAL (TOPIC); COMPLICATION; ETHICS; GRAFT VS HOST DISEASE; LIVING DONOR; MORTALITY; RISK FACTOR; SIBLING;

HLA ANTIGEN;

ANEMIA, SICKLE CELL; CHILD; CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LIVING DONORS; RISK FACTORS; SIBLINGS;

EID: 84905721837     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-575209     Document Type: Review

References (76)

1. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT III. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984;311(12):780-783. (Pubitemid 14026230)
2. Vermylen C, Fernandez Robles E, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anaemia. Lancet. 1988; 1(8600):1427-1428.
3. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335(6):369-376. (Pubitemid 26257244)
4. Walters MC, Patience M, Leisenring W, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665-673. (Pubitemid 34055819)
5. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22(1):1-6. (Pubitemid 28330528)
6. Bernaudin F, Socie G, Kuentz M, et al; SFGM-TC. Long-term results of related myeloablative stemcell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756. (Pubitemid 47523201)
7. Panepinto JA, Walters MC, Carreras J, et al; Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137(5):479-485. (Pubitemid 46698289)
8. Walters MC, Hardy K, Edwards S, et al; Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16(2):263-272.
9. Mynarek M, Bettoni da Cunha Riehm C, Brinkmann F, et al. Normalized transcranial Doppler velocities, stroke prevention and improved pulmonary function after stem cell transplantation in children with sickle cell anemia. Klin Padiatr. 2013;225(3):127-132.
10. Bockenmeyer J, Chamboredon E, Missud F, et al. [Development of psychological and intellectual performance in transplanted sickle cell disease patients: a prospective study from pretransplant period to 5 years after HSCT]. Arch Pediatr. 2013; 20(7):723-730.
11. Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14(11):1270-1278.
12. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309-2317.
13. Majumdar S, Robertson Z, Robinson A, Starnes S, Iyer R, Megason G. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant. 2010;45(5):895-900.
14. Sheth S, Licursi M, Bhatia M. Sickle cell disease: time for a closer look at treatment options? Br J Haematol. 2013;162(4):455-464.
15. Locatelli F, Kabbara N, Ruggeri A, et al; Eurocord and European Blood and Marrow Transplantation (EBMT) group. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLAidentical sibling. Blood. 2013;122(6):1072-1078.
16. Dedeken L, Le PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol. 2014;165(3):402-408.
17. Soni S, Gross TG, Rangarajan H, Baker KS, Sturm M, Rhodes M. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit antithymocyte globulin [published online ahead of print April 17, 2014]. Pediatr Blood Cancer.
18. Soni S, Boulad F, Cowan MJ, et al. Combined umbilical cord blood and bone marrow from HLAidentical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies [published online ahead of print May 7, 2014]. Pediatr Blood Cancer., doi:10.1002/pbc.25085.
19. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5): 1197-1207.
20. King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20): 3089-3094, quiz 3210.
21. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42(5):699-704. (Pubitemid 27481541)
22. Mikles B, Bhatia M, Oyeku SO, Jin Z, Green NS. Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective [published online ahead of print March 13, 2014]. J Pediatr Hematol Oncol.
23. Rogers ZR, Wang WC, Luo Z, et al; BABY HUG. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood. 2011;117(9):2614-2617.
24. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010; 156(1):66-70.
25. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009;146(3): 300-305.
26. Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56(8): 1109-1111. (Pubitemid 32336325)
27. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587-4596.
28. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2): 83-89. (Pubitemid 30036599)
29. Quinn CT, Shull EP, Ahmad N, Lee NJ, Rogers ZR, Buchanan GR. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood. 2007;109(1): 40-45. (Pubitemid 46053040)
30. Sebastiani P, Nolan VG, Baldwin CT, et al. A network model to predict the risk of death in sickle cell disease. Blood. 2007;110(7): 2727-2735. (Pubitemid 47523196)
31. Quinn CT, Lee NJ, Shull EP, Ahmad N, Rogers ZR, Buchanan GR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008;111(2):544-548.
32. Kassim AA, DeBaun MR. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Expert Opin Pharmacother. 2014;15(3):325-336.
33. Meier ER, Byrnes C, Lee YT, et al. Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life. PLoS ONE. 2013;8(8):e70794.
34. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004; 103(11):4023-4027. (Pubitemid 38685339)
35. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-1644.
36. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530-535.
37. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a fourdecade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70(3):206-215. (Pubitemid 34680681)
38. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2): 94-101. (Pubitemid 351651552)
39. McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50.
40. de Montalembert M, Roberts I. Sickle cell disease: primum non nocere (first do no harm). Haematologica. 2010;95(1):4-5.
41. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007;92(7):905-912. (Pubitemid 350144237)
42. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447- 3452.
43. Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;370-376.
44. Lukusa AK, Vermylen C, Vanabelle B, et al. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles. Pediatr Hematol Oncol. 2009;26(4):186-194.
45. Serjeant GR, Serjeant BE, Mason KP, Hambleton IR, Fisher C, Higgs DR. The changing face of homozygous sickle cell disease: 102 patients over 60 years. Int J Lab Hematol. 2009;31(6):585-596.
46. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013;128(2): 110-116.
47. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010; 38(4 Suppl):S512-S521.
48. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer. 2013;60(9):1482-1486.
49. Wierenga KJJ, Hambleton IR, Lewis NA, Unit SC. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357(9257):680-683. (Pubitemid 32206427)
50. Swanson ME, Grosse SD, Kulkarni R. Disability among individuals with sickle cell disease: literature review from a public health perspective. Am J Prev Med. 2011;41(6 Suppl 4):S390-S397.
51. Dampier C, LeBeau P, Rhee S, et al; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011; 86(2):203-205.
52. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140(11):1434-1437. (Pubitemid 10024955)
53. Madu AJ, Ubesie A, Ocheni S, et al. Priapism in homozygous sickle cell patients: important clinical and laboratory associations. Med Princ Pract. 2014;23(3):259-263.
54. Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med. 2012;9(1):88-103.
55. Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol. 2004;103(6): 1278-1285. (Pubitemid 40458962)
56. Fenelon VM, Viana MB, Aguiar RA. Pregnancy in patients with sickle cell disease: maternal and perinatal outcomes [published online ahead of print May 28, 2014]. J Matern Fetal Neonatal Med.
57. Boulet SL, Okoroh EM, Azonobi I, Grant A, Craig Hooper W. Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population. Matern Child Health J. 2013;17(2): 200-207.
58. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93(7): 988-993. (Pubitemid 351957015)
59. Lukusa AK, Vermylen C. Use of hydroxyurea from childhood to adult age in sickle cell disease: semen analysis. Haematologica. 2008;93(11):e67.
60. Kamani N, Lantos JD, Myers D, Kahn JP. Ethical considerations in pediatric BMT donors and recipients. Biol Blood Marrow Transplant. 2011; 17(1 Suppl):S132-S136.
61. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265-1272.
62. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLAhaploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285-4291.
63. Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19(5):820-830.
64. Kharbanda S, Smith AR, Hutchinson SK, et al. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reducedintensity conditioning regimen and third-party mesenchymal stromal cells. Biol Blood Marrow Transplant. 2014;20(4):581-586.
65. Railey MD, Lokhnygina Y, Buckley RH. Longterm clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr. 2009;155(6):834-840.
66. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant. 1995;15(5):663-668.
67. Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant. 2001;27(7):727-730. (Pubitemid 32409448)
68. Zecca M, Prete A, Rondelli R, et al; AIEOP-BMT Group. Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplant. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002;100(4):1192-1200. (Pubitemid 34864271)
69. Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012;79(2):83-89.
70. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6): 1062-1071.
71. McPherson ME, Anderson AR, Castillejo MI, et al. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer. 2010; 54(4):552-558.
72. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood. 2009; 114(11):2315-2322.
73. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73(2): 606-613. (Pubitemid 19060551)
74. van Besien K, Koshy M, Anderson-Shaw L, et al. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant. 2001; 28(6):545-549.
75. Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson FL. Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N Engl J Med. 1991;325(19): 1349-1353.
76. Smith LA, Oyeku SO, Homer C, Zuckerman B. Sickle cell disease: a question of equity and quality. Pediatrics. 2006;117(5):1763-1770. (Pubitemid 46071409)